This story has been updated from a previous version that incorrectly stated the development status of an Alynlam AHP drug candidate.
NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals announced on Thursday that it has expanded a program that provides no-cost genetic testing for people at risk for certain genetic diseases to include acute hepatic porphyrias (AHPs).